# A Study to Select the Dose and Evaluate the Effectiveness and Safety of the Drug Refralon®, Tablets, 1 mg for Long-term Use to Prevent Recurrence of Atrial Fibrillation/Flutter After Terminating Its Persistent Form

> **NCT06540352** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **National Medical Research Center for Cardiology, Ministry of Health of Russian Federation** · enrollment: 175 (actual)

## Conditions studied

- Atrial Fibrillation
- Atrial Flutter

## Interventions

- **DRUG:** 4-Nitro-N-[(1RS)-1-(4-fluorophenyl)-2-(1-ethylpiperidin-4-yl)ethyl]benzamide hydrochloride
- **DRUG:** Mannitol

## Key facts

- **NCT ID:** NCT06540352
- **Lead sponsor:** National Medical Research Center for Cardiology, Ministry of Health of Russian Federation
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-06-03
- **Primary completion:** 2026-12-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 175 (ACTUAL)
- **Last updated:** 2026-04-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06540352

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06540352, "A Study to Select the Dose and Evaluate the Effectiveness and Safety of the Drug Refralon®, Tablets, 1 mg for Long-term Use to Prevent Recurrence of Atrial Fibrillation/Flutter After Terminating Its Persistent Form". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT06540352. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*